Day: November 12, 2021

Recommanded Product: 3-Methyl-1-p-tolyl-5-pyrazolone. In 2021 CHEM-EUR J published article about ENANTIOSELECTIVE ADDITION; TERTIARY ALCOHOLS; PYRAZOLONE DERIVATIVES; ORGANOZINC REAGENTS; ALKYLZINC REAGENTS; ALPHA-KETOESTERS; KETONES; DIETHYLZINC; HYDROXYLATION; DIMETHYLZINC in [Wang, Rong-Hui; Li, Ya-Ling; He, Hong-Jiao; Xiao, You-Cai; Chen, Fen-Er] Sichuan Univ, Sichuan Res Ctr Drug Precis Ind Technol, West China Sch Pharm, Chengdu 610041, Peoples R China; [Chen, Fen-Er] Fudan Univ, Engn Ctr Catalysis & Synth Chiral Mol, Dept Chem, Shanghai 200433, Peoples R China; [Chen, Fen-Er] Shanghai Engn Ctr Ind Asymmetr Catalysis Chiral D, Shanghai 200433, Peoples R China in 2021, Cited 67. The Name is 3-Methyl-1-p-tolyl-5-pyrazolone. Through research, I have a further understanding and discovery of 86-92-0.

The catalytic enantioselective diorganozinc additions to cyclic diketones including pyrazolin-4,5-diones and isatins have been developed. In the presence of morpholine-containing chiral amino alcohol ligand, the corresponding chiral cyclic tertiary alcohols were produced in good to excellent yields (up to 97 %) and enantioselectivities (up to 95 % ee). The notable feature of this protocol includes its mild reaction conditions, Lewis acid additives free and broad functional group tolerance.

Recommanded Product: 3-Methyl-1-p-tolyl-5-pyrazolone. Welcome to talk about 86-92-0, If you have any questions, you can contact Wang, RH; Li, YL; He, HJ; Xiao, YC; Chen, FE or send Email.

Reference:
Article; Zhang, Yong; Nie, Long-Jun; Luo, Liang; Mao, Jia-Xin; Liu, Jin-Xiang; Xu, Guo-Hai; Chen, Deliang; Luo, Hai-Qing; Tetrahedron; vol. 76; 7; (2020);,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

An article VOLATILE PROFILE OF GREEN COFFEE BEANS FROM COFFEA ARABICA L. PLANTS GROWN AT DIFFERENT ALTITUDES IN ETHIOPIA WOS:000496971800002 published article about BIOCHEMICAL-COMPOSITION; ROASTING DEGREE; QUALITY; COMPOUND; AROMA; IDENTIFICATION; FINGERPRINT; COMPONENTS; ODORANTS; CAFFEINE in [Tsegay, Girmay; Redi-Abshiro, Mesfin; Chandravanshi, Bhagwan Singh; Ele, Estifanos; Mohammed, Ahmed M.] Addis Ababa Univ, Coll Nat Sci, Dept Chem, POB 1176, Addis Ababa, Ethiopia; [Tsegay, Girmay] Ethiopian Inst Agr Res, Agr Qual Res Lab, POB 2003, Addis Ababa, Ethiopia; [Mamo, Hassen] Addis Ababa Univ, Coll Nat Sci, Dept Microbial Cellular & Mol Biol, POB 1176, Addis Ababa, Ethiopia in 2019.0, Cited 38.0. Application In Synthesis of 3,5-Dimethyl-1H-pyrazole. The Name is 3,5-Dimethyl-1H-pyrazole. Through research, I have a further understanding and discovery of 67-51-6

This study was aimed to identify volatile compounds of 31 green coffee bean samples and evalute their correlation with altitude of the coffee plants grown in two zones (Gedeo and Jimma) in Ethiopia. A total of 81 different compounds were detected. The contents of dominant volatile compounds in green coffee beans were in the range: trans-linalooloxide (3.24-19.13%), linalool (1.56-21.76%), 2-methoxy-4-vinylphenol (2.34-15.08%) and cis-linalooloxide (1.03-13.27%). In addition, benzene acetaldehyde (0.45-10.97%), 2-heptanol (0.67-8.49%), alpha-terpineol (0.64-6.52%), phenylethyl alcohol (0.44-4.98%) and furfural (0.92-5.3%) were the next dominant compounds. The volatile compounds identified in the green coffee beans are groups of alcohols, aldehydes, ketones, pyrazines, pyridines, and furans. The volatile compounds in green coffee beans showed either weak positive or weak negative correlation with the altitude of coffee plants indicating that variation in altitude of the coffee plants does not significantly influence the volative compounds of green coffee beans.

Welcome to talk about 67-51-6, If you have any questions, you can contact Tsegay, G; Redi-Abshiro, M; Chandravanshi, BS; Ele, E; Mohammed, AM; Mamo, H or send Email.. Application In Synthesis of 3,5-Dimethyl-1H-pyrazole

Reference:
Pyrazole – Wikipedia,
,Pyrazoles – an overview | ScienceDirect Topics

Authors Shaikh, I; Jadeja, RN; Patel, R in PERGAMON-ELSEVIER SCIENCE LTD published article about DNA-BINDING; PLASMODIUM-FALCIPARUM; COPPER(II) COMPLEXES; CU(II) COMPLEXES; DERIVATIVES; ANTICANCER; BINARY in [Shaikh, Irfan; Jadeja, R. N.] Maharaja Sayajirao Univ Baroda, Fac Sci, Dept Chem, Vadodara 390002, India; [Patel, Rajesh] Veer Narmad South Gujarat Univ, Dept Biosci, Surat 395007, India in 2020, Cited 33. Recommanded Product: 86-92-0. The Name is 3-Methyl-1-p-tolyl-5-pyrazolone. Through research, I have a further understanding and discovery of 86-92-0

Three novel mixed ligand Zn(II) complexes {complex 1 = [Zn(L1)(2)(bpy)], complex 2 = [Zn(L2)(2)(bPY)], complex 3 = [Zn(L2)(2)(phen)], where bpy = 2,2′-bipyridine and phen = 1,10-phenanthroline} of 4-(4-chlorobenzoyl)-2-(3-chlorophenyl)-5-methyl-2,4-dihydro-3H-pyrazol-3-one (HL1) and 4-(4-chlorobenzoyl)-5-methyl-2-(p-tolyl)-2,4-dihydro-3H-pyrazol-3-one (HL2) were synthesized and characterized by H-1 and C-13 NMR, FTIR, TG-DTA, UV-Vis, elemental analysis, molar conductance and single crystal X-ray structure determination. Based on analytical and spectroscopic techniques, all the three Zn(II) complexes were found to have a distorted octahedral geometry. The ligands and the complexes were screened for antimalarial activity against plasmodium falciparum. The zinc(II) complexes showed greater antimalarial activity than their parent ligands. (C) 2020 Elsevier Ltd. All rights reserved.

Recommanded Product: 86-92-0. Bye, fridends, I hope you can learn more about C11H12N2O, If you have any questions, you can browse other blog as well. See you lster.

Reference:
Article; Zhang, Yong; Nie, Long-Jun; Luo, Liang; Mao, Jia-Xin; Liu, Jin-Xiang; Xu, Guo-Hai; Chen, Deliang; Luo, Hai-Qing; Tetrahedron; vol. 76; 7; (2020);,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Name: 3-Methyl-1-p-tolyl-5-pyrazolone. In 2021 CHEM-EUR J published article about ENANTIOSELECTIVE ADDITION; TERTIARY ALCOHOLS; PYRAZOLONE DERIVATIVES; ORGANOZINC REAGENTS; ALKYLZINC REAGENTS; ALPHA-KETOESTERS; KETONES; DIETHYLZINC; HYDROXYLATION; DIMETHYLZINC in [Wang, Rong-Hui; Li, Ya-Ling; He, Hong-Jiao; Xiao, You-Cai; Chen, Fen-Er] Sichuan Univ, Sichuan Res Ctr Drug Precis Ind Technol, West China Sch Pharm, Chengdu 610041, Peoples R China; [Chen, Fen-Er] Fudan Univ, Engn Ctr Catalysis & Synth Chiral Mol, Dept Chem, Shanghai 200433, Peoples R China; [Chen, Fen-Er] Shanghai Engn Ctr Ind Asymmetr Catalysis Chiral D, Shanghai 200433, Peoples R China in 2021, Cited 67. The Name is 3-Methyl-1-p-tolyl-5-pyrazolone. Through research, I have a further understanding and discovery of 86-92-0.

The catalytic enantioselective diorganozinc additions to cyclic diketones including pyrazolin-4,5-diones and isatins have been developed. In the presence of morpholine-containing chiral amino alcohol ligand, the corresponding chiral cyclic tertiary alcohols were produced in good to excellent yields (up to 97 %) and enantioselectivities (up to 95 % ee). The notable feature of this protocol includes its mild reaction conditions, Lewis acid additives free and broad functional group tolerance.

Name: 3-Methyl-1-p-tolyl-5-pyrazolone. Welcome to talk about 86-92-0, If you have any questions, you can contact Wang, RH; Li, YL; He, HJ; Xiao, YC; Chen, FE or send Email.

Reference:
Article; Zhang, Yong; Nie, Long-Jun; Luo, Liang; Mao, Jia-Xin; Liu, Jin-Xiang; Xu, Guo-Hai; Chen, Deliang; Luo, Hai-Qing; Tetrahedron; vol. 76; 7; (2020);,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Cimino, S; Verze, P; Venturino, L; Alessio, P; Migliara, A; Imbimbo, C; Mirone, V; Russo, GI; Morgia, G in [Cimino, Sebastiano; Verze, Paolo; Venturino, Luca; Alessio, Paolo; Migliara, Alfonso; Imbimbo, Ciro; Mirone, Vincenzo; Russo, Giorgio Ivan; Morgia, Giuseppe] Univ Catania, Dept Urol, Urol Sect, Catania, Italy; [Cimino, Sebastiano; Verze, Paolo; Venturino, Luca; Alessio, Paolo; Migliara, Alfonso; Imbimbo, Ciro; Mirone, Vincenzo; Russo, Giorgio Ivan; Morgia, Giuseppe] Univ Naples Federico II, Dept Neurosci Reprod Sci & Odontostomatol, Naples, Italy published Complication Rate After Antibiotic Prophylaxis with Fosfomycin Versus Fluorochinolones or beta-lactam Antibiotics in Patients Undergoing Prostate Biopsy: A Propensity Score-adjusted Analysis in 2020.0, Cited 18.0. HPLC of Formula: C5H8N2. The Name is 3,5-Dimethyl-1H-pyrazole. Through research, I have a further understanding and discovery of 67-51-6.

Background: Transrectal ultrasound-guided prostate biopsy (TRBx) or transperineal Bx (TPBx) are considered alternative approaches for the diagnosis of prostate cancer (PCa). However, urinary tract infection (UTI) or other complications could be more frequent in the TRBx approach. Objective: To determine the complication rate following different antimicrobial prophylaxis (AMP; fosfomycin trometamol [FT] vs beta-lactame or fluorochinolones [FQ]) in patients undergoing TRBx or TPBx. Design, setting, and participants: The analyses were based on prospectivelycollected data of a cohort of patients who underwent TRBx or TPBx for elevated prostate-specific antigen (PSA; >= 4 ng/ml) or clinical suspicion of PCa, between September 2016 and March 2017. Patients received a single dose of 3 g oral FT (group A) or, alternatively, FQ or beta-lactame (group B). Intervention:TRBx versus TPBx. Outcome measurements and statistical analysis: Adjustment variables consisted of age, PSA, biopsy technique (TPBx vs TRBx), and antibiotic prophylaxis (FT vs beta-lactame or FQ) using 1:1 propensity-score matching. Overall, 526 patients were considered, of whom 258 received FT (group A) and the other 258 received beta-lactame or FQ (group B). Results and limitations: Overall complications occurred in 390 (75.58%) and major complications in 67/516 (12.98%). Lower prevalence of UTIs was detected in group A (34.1%) compared with that in group B (43.4%; p = 0.03), while similar rates of haematuria (54.7% vs 55.4%), haemospermia (39.5% vs 33.0%), and acute urinary retention (11.6% vs 9.3%) were detected in groups A and B. We found that group B (odds ratio [OR]: 1.54; p = 0.03), I grade haematuria (OR: 6.17; p < 0.01), and II grade haematuria (OR: 5.13; p < 0.01) were significantly associated with increased risk of UTIs. Conclusions: AMP with fluoroquinoles or beta-lactam antibiotics increased the rate of UTIs, when compared with FT, in patients undergoing TRBx or TPBx. The appearance of haematuria or haemospermia is associated with UTIs, suggesting the possibility of tailoring the strategy for prophylaxis in this category of patients. Patient summary: In this study, comparing complications after transrectal ultrasound-guided prostate biopsy versus transperineal biopsy, prophylaxis with fluoroquinoles or beta-lactam antibiotics increased the rate of urinary tract infections when compared with fosfomycin trometamol, regardless of the type of biopsy approach. (C) 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved. HPLC of Formula: C5H8N2. Welcome to talk about 67-51-6, If you have any questions, you can contact Cimino, S; Verze, P; Venturino, L; Alessio, P; Migliara, A; Imbimbo, C; Mirone, V; Russo, GI; Morgia, G or send Email.

Reference:
Pyrazole – Wikipedia,
,Pyrazoles – an overview | ScienceDirect Topics

In 2020.0 J ORG CHEM published article about 2+2 PHOTOCYCLOADDITION REACTIONS; PHOTOREDOX CATALYSIS; BRONSTED ACID; THIOXANTHONE; ALKYLATION; ELECTRON; ACTIVATION; AMINATION; THIOUREA in [Lyu, Jiyuan; Claraz, Aurelie; Masson, Geraldine] Univ Paris Saclay, UPR2301, CNRS, Inst Chim Subst Nat, F-91198 Gif Sur Yvette, France; [Lyu, Jiyuan; Allain, Clemence] Univ Paris Saclay, ENS Paris Saclay, PPSM, CNRS, F-91190 Gif Sur Yvette, France; [Vitale, Maxime R.] PSL Univ, Sorbonne Univ, CNRS, Lab Biomol,LBM,Dept Chim,Ecole Normale Super, F-75005 Paris, France in 2020.0, Cited 70.0. The Name is 3,5-Dimethyl-1H-pyrazole. Through research, I have a further understanding and discovery of 67-51-6. Quality Control of 3,5-Dimethyl-1H-pyrazole

Chiral phosphoric acid based organocatalysis and visible-light photocatalysis have both emerged as promising technologies for the sustainable production of fine chemicals. In this context, we have envisioned the design and the synthesis of a new class of chimeric catalytic entities that would feature both catalytic capabilities. Given their multitask nature, such catalysts would be particularly attractive for the development of new catalytic transformations, tandem processes in particular. Toward this goal, several BINOL-based chiral phosphoric acid backbones presenting one or two visible-light-sensitive thioxanthone moieties have been prepared and studied. The utility of these new photoactive chiral organocatalysts is then demonstrated in the enantioselective tandem three-component electrophilic amination of enecarbamates. Of note, the C-1-symmetric organo/photocatalyst has shown a better catalytic activity than those presenting a C-2 symmetry.

Quality Control of 3,5-Dimethyl-1H-pyrazole. Welcome to talk about 67-51-6, If you have any questions, you can contact Lyu, JY; Claraz, A; Vitale, MR; Allain, C; Masson, G or send Email.

Reference:
Pyrazole – Wikipedia,
,Pyrazoles – an overview | ScienceDirect Topics

Recently I am researching about HENRY NITROALDOL REACTIONS; ORGANIC-SYNTHESIS; ON-WATER; DERIVATIVES; ANTIPYRINE; ALCOHOLS; HETEROCYCLES; CHEMISTRY; CYCLIZATION; EFFICIENT, Saw an article supported by the Jiangxi Provincial Department of Science and Technology Fund [20192BAB213007]; Education Department of Jiangxi Province [G11170835]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [21865003, 21763002]. Application In Synthesis of 3-Methyl-1-p-tolyl-5-pyrazolone. Published in PERGAMON-ELSEVIER SCIENCE LTD in OXFORD ,Authors: Zhang, Y; Nie, LJ; Luo, L; Mao, JX; Liu, JX; Xu, GH; Chen, DL; Luo, HQ. The CAS is 86-92-0. Through research, I have a further understanding and discovery of 3-Methyl-1-p-tolyl-5-pyrazolone

The selective condensation of pyrazolones with isatins using water as the reaction medium is presented. This strategy provides an environmentally benign synthetic route to synthesize various potentially bioactive pyrazolone substituted oxindoles. (C) 2020 Elsevier Ltd. All rights reserved.

Welcome to talk about 86-92-0, If you have any questions, you can contact Zhang, Y; Nie, LJ; Luo, L; Mao, JX; Liu, JX; Xu, GH; Chen, DL; Luo, HQ or send Email.. Application In Synthesis of 3-Methyl-1-p-tolyl-5-pyrazolone

Reference:
Article; Zhang, Yong; Nie, Long-Jun; Luo, Liang; Mao, Jia-Xin; Liu, Jin-Xiang; Xu, Guo-Hai; Chen, Deliang; Luo, Hai-Qing; Tetrahedron; vol. 76; 7; (2020);,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

I found the field of Oncology very interesting. Saw the article Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients published in 2020. Recommanded Product: 83-10-3, Reprint Addresses Buchler, T (corresponding author), Charles Univ Prague, Fac Med 1, Dept Oncol, Videnska 800, Prague 14059, Czech Republic.; Buchler, T (corresponding author), Charles Univ Prague, Thomayer Hosp, Videnska 800, Prague 14059, Czech Republic.. The CAS is 83-10-3. Through research, I have a further understanding and discovery of 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid

Purpose: Regorafenib is an oral multikinase inhibitor approved for the therapy of previously treated metastatic colorectal carcinoma (mCRC). The aim of the present study was to analyze the outcomes of treatment with regorafenib in real-world clinical practice based on data from a national registry. Methods: The CORECT registry, the Czech non-interventional database of patients with mCRC treated with targeted agents, searched for patients with metastatic CRC treated with regorafenib. In total, 555 evaluable patients were identified. Results: The median age at diagnosis was 61.7 years. All patients had disease progression on or after previous systemic treatment. Most patients were treated with an initial dose of 160 mg daily (n = 463; 83.6%). The median duration of treatment was 2.7 months (range 0.023.4 months). By the data cut-off date, 472 patients (85%) had completed treatment with regorafenib and were evaluable for treatment response evaluation. Partial response was reported in 13 patients (2.8%) and disease stabilization in 130 patients (27.5%). Median progression-free survival (PFS) and overall survival (OS) were 3.5 months (95% confidence interval [CI] 3.2-3.7 months) and 9.3 months (95% CI 8.3-10.3 months), respectively. The 6-month OS rate was 67.7% (95% CI 63.4-72.1%). Multivariable analysis showed that female gender, longer interval from diagnosis of metastatic disease, MO stage at diagnosis, and Eastern Cooperative Oncology Group performance status (ECOG PS) 0 were associated with longer PFS, while higher body-mass index (BMI), longer interval from diagnosis of metastatic disease, and ECOG PS of 0 were associated with longer OS. Conclusion: OS of patients treated with regorafenib in the real-world clinical practice in this cohort exceeded that reported in randomized trials. Regorafenib is a safe and active treatment option for a subgroup of patients with mCRC who are progressing after other systemic therapies and maintain good performance status.

Recommanded Product: 83-10-3. Bye, fridends, I hope you can learn more about C12H12N2O3, If you have any questions, you can browse other blog as well. See you lster.

Reference:
Patent; Shanghai Pharmaceutical Industry Institute; China Pharmaceutical Industry Zongyuan; Li Jianqi; Huang Daowei; Wang Wenya; Zhang Zhiguo; Jiang Ling; (45 pag.)CN107286140; (2017); A;,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

An article Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients WOS:000548281000003 published article about CLINICAL-PRACTICE; SURVIVAL; MULTICENTER; ANTITUMOR; SAFETY; SITE; SEX in [Novakova-Jiresova, Alena; Boublikova, Ludmila; Buchler, Tomas] Charles Univ Prague, Fac Med 1, Dept Oncol, Videnska 800, Prague 14059, Czech Republic; [Novakova-Jiresova, Alena; Boublikova, Ludmila; Buchler, Tomas] Charles Univ Prague, Thomayer Hosp, Videnska 800, Prague 14059, Czech Republic; [Kopeckova, Katerina; Batko, Stanislav; Linke, Zdenek; Prausov, Jana] Charles Univ Prague, Univ Hosp Motol, Dept Oncol, Prague, Czech Republic; [Chloupkov, Renata] Masaryk Univ, Fac Med, Inst Biostat & Anal, Brno, Czech Republic; [Melichar, Bohuslav] Palacky Univ Med, Dept Oncol, Olomouc, Czech Republic; [Melichar, Bohuslav] Teaching Hosp, Olomouc, Czech Republic; [Petruzelka, Lubos] Charles Univ Prague, Gen Fac Hosp, Dept Oncol, Prague, Czech Republic; [Finek, Jindrich; Fiala, Ondrej] Charles Univ Prague, Med Sch, Dept Oncol & Radiotherapy, Plzen, Czech Republic; [Finek, Jindrich; Fiala, Ondrej] Charles Univ Prague, Univ Hosp Pilsen, Plzen, Czech Republic; [Fiala, Ondrej] Charles Univ Prague, Fac Med Pilsen, Biomed Ctr, Plzen, Czech Republic; [Grell, Peter; Kiss, Igor] Masaryk Mem Canc Inst, Dept Comprehens Canc Care, Brno, Czech Republic in 2020, Cited 30. The Name is 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid. Through research, I have a further understanding and discovery of 83-10-3. COA of Formula: C12H12N2O3

Purpose: Regorafenib is an oral multikinase inhibitor approved for the therapy of previously treated metastatic colorectal carcinoma (mCRC). The aim of the present study was to analyze the outcomes of treatment with regorafenib in real-world clinical practice based on data from a national registry. Methods: The CORECT registry, the Czech non-interventional database of patients with mCRC treated with targeted agents, searched for patients with metastatic CRC treated with regorafenib. In total, 555 evaluable patients were identified. Results: The median age at diagnosis was 61.7 years. All patients had disease progression on or after previous systemic treatment. Most patients were treated with an initial dose of 160 mg daily (n = 463; 83.6%). The median duration of treatment was 2.7 months (range 0.023.4 months). By the data cut-off date, 472 patients (85%) had completed treatment with regorafenib and were evaluable for treatment response evaluation. Partial response was reported in 13 patients (2.8%) and disease stabilization in 130 patients (27.5%). Median progression-free survival (PFS) and overall survival (OS) were 3.5 months (95% confidence interval [CI] 3.2-3.7 months) and 9.3 months (95% CI 8.3-10.3 months), respectively. The 6-month OS rate was 67.7% (95% CI 63.4-72.1%). Multivariable analysis showed that female gender, longer interval from diagnosis of metastatic disease, MO stage at diagnosis, and Eastern Cooperative Oncology Group performance status (ECOG PS) 0 were associated with longer PFS, while higher body-mass index (BMI), longer interval from diagnosis of metastatic disease, and ECOG PS of 0 were associated with longer OS. Conclusion: OS of patients treated with regorafenib in the real-world clinical practice in this cohort exceeded that reported in randomized trials. Regorafenib is a safe and active treatment option for a subgroup of patients with mCRC who are progressing after other systemic therapies and maintain good performance status.

COA of Formula: C12H12N2O3. Bye, fridends, I hope you can learn more about C12H12N2O3, If you have any questions, you can browse other blog as well. See you lster.

Reference:
Patent; Shanghai Pharmaceutical Industry Institute; China Pharmaceutical Industry Zongyuan; Li Jianqi; Huang Daowei; Wang Wenya; Zhang Zhiguo; Jiang Ling; (45 pag.)CN107286140; (2017); A;,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

COA of Formula: C11H12N2O. In 2019 TETRAHEDRON LETT published article about AGENTS; DERIVATIVES in [Zhu, Ye-Fu; Wei, Bo-Le; Wei, Jiao-Jiao; Wang, Wen-Qiong; Song, Wei-Bin; Xuan, Li-Jiang] Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, 501 Haike Rd,Zhangjiang Hitech Pk, Shanghai 201203, Peoples R China; [Zhu, Ye-Fu; Wei, Bo-Le; Wei, Jiao-Jiao] Univ Chinese Acad Sci, 19A Yuquan Rd, Beijing 100049, Peoples R China in 2019, Cited 18. The Name is 3-Methyl-1-p-tolyl-5-pyrazolone. Through research, I have a further understanding and discovery of 86-92-0.

A palladium-catalyzed oxidative dehydrogenation reaction in the presence of AMS and base to synthesize pyrazolones and pyrazoles was identified. This method can be utilized to a wide range of substrates, operates under mild react conditions and can give high yields. We believe it could be used as an alternative protocol for the classical dehydrogenation reactions. (C) 2019 Published by Elsevier Ltd.

Bye, fridends, I hope you can learn more about C11H12N2O, If you have any questions, you can browse other blog as well. See you lster.. COA of Formula: C11H12N2O

Reference:
Article; Zhang, Yong; Nie, Long-Jun; Luo, Liang; Mao, Jia-Xin; Liu, Jin-Xiang; Xu, Guo-Hai; Chen, Deliang; Luo, Hai-Qing; Tetrahedron; vol. 76; 7; (2020);,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics